Autopsy report · NCT02370329
P1101 in Treating Patients With Myelofibrosis
Cause of deathFunding or business
“Study drug became commercially available”
Life of this trial
- Registered 6 months before it started.
- Ran for about 8 years 4 months before it stopped.
- 11 participants enrolled.
- Results were posted on the registry 1 year 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Conditions
- Primary Myelofibrosis; Secondary Myelofibrosis
- Interventions
- Laboratory Biomarker Analysis; Quality-of-Life Assessment; Ropeginterferon Alfa-2B
- Participants
- 11
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
“Study drug is now commercially available in tablet format” - CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
“Study drug no longer available” - A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
“One of the drugs for the study is not commercially available.” - Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
“study drug unavailable” - An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
“Study medication was no longer available for study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.